250 related articles for article (PubMed ID: 27012596)
1. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
3. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.
Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Somogyi M
CNS Neurosci Ther; 2013 Oct; 19(10):745-52. PubMed ID: 23924050
[TBL] [Abstract][Full Text] [Related]
4. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
5. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
7. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study.
Yatawara C; Zailan FZ; Chua EV; Lim LLH; Silva E; Wang JS; Ng A; Ng KP; Kandiah N
Clin Interv Aging; 2021; 16():301-309. PubMed ID: 33642856
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
[TBL] [Abstract][Full Text] [Related]
10. Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease.
Jia J; Ji Y; Feng T; Ye Q; Peng D; Kuang W; Ning Y; Liang Z; Fan D; Wei W; Li Y; Xiao S
J Alzheimers Dis; 2019; 72(4):1313-1322. PubMed ID: 31744005
[TBL] [Abstract][Full Text] [Related]
11. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
13. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.
D'Onofrio G; Sancarlo D; Addante F; Ciccone F; Cascavilla L; Paris F; Elia AC; Nuzzaci C; Picoco M; Greco A; Panza F; Pilotto A
Int J Geriatr Psychiatry; 2015 Sep; 30(9):965-75. PubMed ID: 25504466
[TBL] [Abstract][Full Text] [Related]
14. Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Grossberg GT; Farlow MR; Meng X; Velting DM
Curr Alzheimer Res; 2015; 12(1):53-60. PubMed ID: 25523430
[TBL] [Abstract][Full Text] [Related]
15. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
Grossberg G; Meng X; Olin JT
Am J Alzheimers Dis Other Demen; 2011 Feb; 26(1):65-71. PubMed ID: 21282280
[TBL] [Abstract][Full Text] [Related]
16. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
17. Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease.
Isaacson RS; Ferris S; Velting DM; Meng X
Am J Alzheimers Dis Other Demen; 2016 May; 31(3):270-7. PubMed ID: 26371345
[TBL] [Abstract][Full Text] [Related]
18. The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.
Farlow MR; Doraiswamy PM; Meng X; Cooke K; Somogyi M
Dement Geriatr Cogn Dis Extra; 2011 Jan; 1(1):150-62. PubMed ID: 22163241
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]